Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company, focuses on developing groundbreaking gene therapies and vaccines for various impairments. The company operates in a competitive environment with peers like Bionano Genomics and others.

In examining Ocugen’s financial performance, one vital metric is the Return on Invested Capital (ROIC), currently resting at -118.07%. This falls significantly short of the company’s Weighted Average Cost of Capital (WACC) at 21.99%.

Compared to its competitors, Bionano Genomics has a slightly worse ROIC, revealing efficiency issues across the sector. As the biopharmaceutical industry often grapples with myriad challenges, it’s clear that Ocugen, like many, faces hurdles in exceeding its cost of capital.